Prenatal Dexamethasone Exposure Programs the Development of the Pancreas and the Secretion of Insulin in Rats

Area of Science:

• Endocrinology
• Developmental Biology
• Toxicology

Background:

• Chronic diseases often originate in early life, influenced by fetal programming.
• Prenatal glucocorticoid therapy, while used for lung maturation, has unclear long-term consequences.
• Understanding these effects is crucial for prenatal care and disease prevention.

Purpose of the Study:

• To investigate the long-term effects of prenatal dexamethasone exposure on pancreatic development and function in rats.
• To assess the impact on beta cell mass, insulin secretion, and related gene expression.
• To elucidate potential mechanisms of fetal programming on pancreatic health.

Main Methods:

• Pregnant Sprague-Dawley rats received dexamethasone or vehicle from Gestational Days 14-20.
• Pancreas was analyzed at Postnatal Days 7 and 120.
• Evaluated beta cell fractions, insulin secretion, gene expression (PDX1, MAFA), histone deacetylase activity, and oxidative stress markers (8-OHdG).

Main Results:

• Prenatal dexamethasone led to fewer pancreatic beta cells and tissues at Postnatal Day 120.
• Insulin secretion in response to glucose was decreased at Postnatal Day 105.
• Early postnatal exposure (Day 7) showed altered expression of PDX1 and MAFA, increased histone deacetylase activity, and elevated oxidative stress.

Conclusions:

• Prenatal dexamethasone exposure significantly impacts early postnatal gene expression crucial for pancreas development.
• These changes may negatively affect beta-cell development and function later in life.
• The findings suggest a potential link between prenatal glucocorticoid exposure and long-term metabolic dysfunction via fetal programming.